← All companies ← VMI Manual VNO → ← UTHR Pharmaceuticals VRDN →
VNDA, Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
HETLIOZ is the first product approved by the United States Food and Drug Administration (FDA) for patients with Non-24 and for patients with SMS.
The business
What it sells, where the money comes from, the kind of company it is.
Next report By 11/8 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~37 days after · the wire records it on arrival
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- What it is
- Revenue is Fanapt (54%), Hetlioz (33%) and PONVORY (13%).
- Situation
- Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
- What moves the needle
- Operating margin has reached 16% at its best but run negative through the cycle (median −2.4%) — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Stock-based pay runs about 5.9% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median −0%, above 15% in 0 of 10 years). By owner earnings: roughly 9% of revenue reaches owners as cash, though it swings. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 10-K →Revenue spreads across 3 lines, the largest Fanapt at 54%.
- Fanapt54%$117M
- Hetlioz33%$71M
- PONVORY13%$27M
From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $146M | $165M | $193M | $227M | $248M | $269M | $254M | $193M | $199M | $216M | $216M | RevenueRevenue |
| 68% | 75% | 55% | 57% | 57% | 46% | 54% | 59% | 74% | 110% | 122% | SG&A / revenueSG&A/rev |
| 20% | 23% | 23% | 21% | 22% | 28% | 34% | 40% | 37% | 51% | 54% | R&D / revenueR&D/rev |
| ($19M) | ($17M) | $22M | $23M | $27M | $42M | $6M | ($14M) | ($41M) | ($151M) | ($186M) | Operating incomeOp. inc. |
| −12.7% | −10.2% | 11.3% | 10.0% | 11.0% | 15.7% | 2.5% | −7.2% | −20.5% | −70.0% | −86.1% | Operating marginOp. mgn |
| ($18M) | ($15M) | $25M | $29M | $32M | $42M | $11M | $6M | ($23M) | ($139M) | — | Pretax incomePretax |
| ($18M) | ($16M) | $25M | $116M | $23M | $33M | $6M | $3M | ($19M) | ($220M) | ($275M) | Net incomeNet inc. |
| — | — | 1% | — | 26% | 22% | 44% | — | — | — | — | Effective tax rateTax rate |
| Cash flow & returns | |||||||||||
| ($8M) | ($2M) | $30M | $46M | $52M | $64M | $32M | $13M | ($16M) | ($109M) | ($142M) | Operating cash flowOp. cash |
| $935K | $1M | $1M | $1M | $1M | $1M | $1M | $920K | $859K | $1M | $1M | DepreciationDeprec. |
| $429K | $2M | ($8M) | ($84M) | $14M | $14M | $8M | ($5M) | ($10M) | $100M | $122M | Working capital & otherWC & other |
| $1M | $2M | $368K | $1M | $2M | $552K | $679K | $383K | $490K | $998K | $674K | CapexCapex |
| 1.0% | 1.0% | 0.2% | 0.4% | 0.7% | 0.2% | 0.3% | 0.2% | 0.2% | 0.5% | 0.3% | Capex / revenueCapex/rev |
| ($9M) | ($3M) | $30M | $45M | $50M | $64M | $31M | $12M | ($16M) | ($110M) | ($143M) | Owner earningsOwner earn. |
| −6.2% | −1.9% | 15.3% | 19.8% | 20.3% | 23.7% | 12.3% | 6.4% | −8.2% | −51.1% | −66.3% | Owner earnings marginOE mgn |
| ($10M) | ($4M) | $30M | $45M | $50M | $64M | $31M | $12M | ($16M) | ($110M) | ($143M) | Free cash flowFCF |
| −6.5% | −2.2% | 15.3% | 19.8% | 20.1% | 23.7% | 12.3% | 6.4% | −8.2% | −51.1% | −66.3% | Free cash flow marginFCF mgn |
| ($10M) | ($10M) | ($110M) | ($68M) | ($41M) | ($77M) | $50M | ($12M) | ($17M) | $95M | — | Investing cash flowInv. cash |
| $8M | $5M | $107M | $6M | $6M | $4M | $734K | $0 | ($155K) | ($3M) | — | Financing cash flowFin. cash |
| $5K | $42K | ($38K) | ($1K) | $53K | ($91K) | $265K | $47K | ($163K) | $23K | — | Exchange-rate effectFX |
| ($10M) | ($7M) | $27M | ($16M) | $16M | ($9M) | $83M | $792K | ($34M) | ($17M) | — | Change in cashΔ cash |
| -16% | -14% | 10% | 6% | 5% | 7% | 1% | -2% | -7% | -49% | -89% | ROICROIC |
| -14% | -12% | 9% | 28% | 5% | 7% | 1% | 0% | -4% | -67% | -125% | Return on equityROE |
| −14% | −12% | 9% | 28% | 5% | 7% | 1% | 0% | −4% | −67% | −125% | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| $40M | $34M | $61M | $45M | $61M | $52M | $135M | $136M | $102M | $85M | $56M | Cash & investmentsCash+inv |
| $20M | $18M | $29M | $26M | $30M | $32M | $34M | $34M | $47M | $55M | $60M | ReceivablesReceiv. |
| $779K | $840K | $994K | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | InventoryInvent. |
| $16M | $20M | $22M | $28M | $32M | $34M | $46M | $38M | $39M | $68M | $8M | Accounts payablePayables |
| $5M | ($2M) | $8M | ($83K) | ($193K) | ($946K) | ($11M) | ($3M) | $10M | ($12M) | $53M | Operating working capitalOper. WC |
| $174M | $170M | $299M | $354M | $409M | $478M | $519M | $433M | $439M | $347M | $264M | Current assetsCur. assets |
| $50M | $70M | $53M | $60M | $66M | $74M | $91M | $88M | $100M | $145M | $164M | Current liabilitiesCur. liab. |
| 3.5× | 2.4× | 5.6× | 6.0× | 6.2× | 6.4× | 5.7× | 4.9× | 4.4× | 2.4× | 1.6× | Current ratioCurr. ratio |
| $5M | $5M | $4M | $4M | $4M | $3M | $3M | $2M | $2M | $2M | — | Net PP&ENet PP&E |
| $210M | $205M | $332M | $484M | $533M | $594M | $634M | $648M | $656M | $489M | $412M | Total assetsAssets |
| ($40M) | ($34M) | ($61M) | ($45M) | ($61M) | ($52M) | ($135M) | ($136M) | ($102M) | ($85M) | ($56M) | Net debt / (cash)Net debt |
| $79M | $74M | $57M | $73M | $80M | $89M | $107M | $104M | $118M | $162M | — | Total liabilitiesTotal liab. |
| $131M | $131M | $275M | $411M | $453M | $505M | $527M | $545M | $539M | $327M | $220M | Shareholders’ equityEquity |
| 5.9% | 6.3% | 6.0% | 5.9% | 5.4% | 5.7% | 6.4% | 7.3% | 6.3% | 4.4% | 4.2% | Stock comp / revenueSBC/rev |
| Per share | |||||||||||
| 43.4M | 44.7M | 53.0M | 54.8M | 55.2M | 56.9M | 57.0M | 57.6M | 58.1M | 58.9M | 59.8M | Shares out (diluted)Shares |
| $3.36 | $3.69 | $3.64 | $4.14 | $4.50 | $4.72 | $4.46 | $3.35 | $3.42 | $3.67 | $3.60 | Revenue / shareRev/sh |
| $-0.41 | $-0.35 | $0.48 | $2.11 | $0.42 | $0.58 | $0.11 | $0.04 | $-0.33 | $-3.74 | $-4.59 | EPS (diluted)EPS |
| $-0.21 | $-0.07 | $0.56 | $0.82 | $0.91 | $1.12 | $0.55 | $0.22 | $-0.28 | $-1.87 | $-2.39 | Owner earnings / shareOE/sh |
| $-0.22 | $-0.08 | $0.56 | $0.82 | $0.91 | $1.12 | $0.55 | $0.22 | $-0.28 | $-1.87 | $-2.39 | Free cash flow / shareFCF/sh |
| $0.03 | $0.04 | $0.01 | $0.02 | $0.03 | $0.01 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 | Cap. spending / shareCapex/sh |
| $3.02 | $2.94 | $5.19 | $7.49 | $8.21 | $8.87 | $9.25 | $9.47 | $9.26 | $5.55 | $3.68 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +1.0%/yr | −4.0%/yr |
| Capital spending / share | −6.9%/yr | −12.2%/yr |
| Book value / share | +7.0%/yr | −7.5%/yr |
The year, in the company's words
the filing →Verbatim from the 10-K's management discussion. Each sentence is shown only because its subject, direction, and stated figures check out against the filed numbers on this page. The words are the company's; the arithmetic is the record's.
- Hetlioz-6.8%
“HETLIOZ® net product sales decreased by $5.2 million, or 7%, to $71.4 million for the year ended December 31, 2025 compared to $76.7 million for the year ended December 31, 2024. The decrease to net product sales was attributable to a decrease in volume and price, net of deductions.”
✓ figure matches the filed record
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedEach year's operating cash, by what management did with it: the mix, and how it drifts.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned a $220M loss into ($110M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | ($220M) | ($19M) | $3M | $6M | $33M |
| Depreciationnon-cash charge added back | +$1M | +$859K | +$920K | +$1M | +$1M |
| Amortization of intangible assetsnon-cash charge added back; the purchase price of past acquisitions, expensed over time | +$7M | +$7M | +$2M | +$2M | +$1M |
| Stock-based compensationreal costnon-cash, but a real cost | +$9M | +$12M | +$14M | +$16M | +$15M |
| Working capital & othertiming of cash in and out, other non-cash items | +$93M | −$17M | −$7M | +$7M | +$13M |
| Cash from operations | ($109M) | ($16M) | $13M | $32M | $64M |
| Capital expenditurecash put back in to keep running and to grow | −$998K | −$490K | −$383K | −$679K | −$552K |
| Owner earnings | ($110M) | ($16M) | $12M | $31M | $64M |
| Owner-earnings marginowner earnings ÷ revenue | -51% | -8% | 6% | 12% | 24% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $9M), owner earnings is nearer ($120M).
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- No meaningful interest burdenLittle or no interest expense reported
What this means
Little or no interest expense reported, the business isn't leaning on lenders to operate.
- Net cash, debt-freeCash $85M − debt $0
What this means
Cash and short-term investments exceed every dollar of debt by $85M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Not enough data
What this means
The filing data didn't include the inputs for this check.
Is it a good business?
- Not enough dataIndustry peers: median -59%
What this means
The filing data didn't include the inputs for this check.
- Solid through the cycle10-yr median margin, range -51%–24%; latest ($110M) = operating cash ($109M) − maintenance capex $998KIndustry peers: median -132%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -51% of revenue this year, a 9% median across 10 years. Treating stock comp as the real expense it is (less $9M of SBC) leaves ($120M).
- Are earnings backed by cash? ($109M)Loss, and burning cashNet income ($220M) · cash from operations ($109M)
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.90×MaintainingCapex $998K ÷ property depreciation $1M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
The promise and the pay packet
- Is the buyback buying ownership, or mopping up? 4.4%The count is risingStock compensation $9M (fiscal 2025), 4.4% of revenue · no repurchases · diluted shares +3.4% since 2022
What this means
Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.
Graham’s defensive tests · 1 of 3 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $216M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 2.39×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Earnings stability MissA profit every year (10-yr record) · 4 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record —Uninterrupted dividends · no dividend line tagged in the data
What this means
An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-1.31/share (latest year $-3.65), the averaged base the calculator's gate runs on, and book value is $5.41/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 6 of 10
What this means
Lost money in 4 year(s), look at what happened there before trusting the average.
- Operating margin −4% → −33% (3-yr avg ends)
What this means
Through the cycle the operating margin slipped — about −4% early to −33% lately, median −7% — competition or costs are biting in.
- Worst year 2025 · −70.0% op. margin
What this means
Operations went underwater in 2025, understand why before trusting the good years.
- Share count +3.4%/yr
What this means
The share count is rising, dilution works against you on a per-share basis.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Jun 30, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$56M
- Receivables$60M
- Inventory$2M
- Other current assets$147M
- Accounts payable$70M
- Other current liabilities$94M
From the company's latest filing.
How the cash was used, 2016–2025
Over the record, the business generated $101M of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested$9M · 9%
- Retained (debt / cash)$92M · 91%
- Net change in share count37.7%
The diluted count rose from 43M to 60M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.
- Dividend record—
No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.
| Fiscal year | Chief executive | Pay, as filed | “Actually paid” | Owner earnings |
|---|---|---|---|---|
| 2021 | Dr. Mihael H. Polymeropoulos | $6.2M | $5.6M | $64M |
| 2022 | Dr. Mihael H. Polymeropoulos | $4.3M | $860k | $31M |
| 2023 | Dr. Mihael H. Polymeropoulos | $3.7M | $1.8M | $12M |
| 2024 | Dr. Mihael H. Polymeropoulos | $3.9M | $4.3M | ($16M) |
| 2025 | Dr. Mihael H. Polymeropoulos | $3.9M | $7.6M | ($110M) |
Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.
- Insider ownership10.7%
The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.
- Stock-based compensation$9M
The slice of the business handed to employees in shares in fiscal 2025, 4.4% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.
| Company | Revenuelatest FY, USD | Gross marginmedian over the record | Op. marginmedian over the record | ROICmedian over the record | Owner earn. marginmedian over the record |
|---|---|---|---|---|---|
| RCUSArcus Biosciences Inc. | $247M | — | -204.5% | -55% | -132% |
| AKBAAkebia Therapeutics Inc. | $236M | 62% | -42.3% | -116% | -31% |
| ANABAnaptysBio Inc. | $235M | — | -60.9% | -25% | -64% |
| PBYIPuma Biotechnology Inc | $228M | 76% | 5.5% | -59% | 8% |
| IDYAIDEAYA Biosciences Inc. | $219M | — | -179.9% | -22% | -175% |
| VNDAVanda Pharmaceuticals Inc. | $216M | — | -2.4% | -0% | 9% |
| RYTMRhythm Pharmaceuticals Inc. | $190M | 90% | -221.1%4y | -67% | -132%4y |
| STOKStoke Therapeutics Inc. | $184M | — | -277.3% | -79% | -238% |
| Group median | — | — | -120.4% | -57% | -98% |
The price
What a price has to assume.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Vanda Pharmaceuticals Inc. has delivered.
Vanda Pharmaceuticals Inc.’s latest year shows negative owner earnings, a cyclical trough. So the tool opens on the through-cycle base, the cash it would earn at rest; clear the toggle below to read the latest year exactly as reported.
Through the cycle, Vanda Pharmaceuticals Inc. earns about $20M on its 9.4% median owner-earnings margin. This year’s −51.1% margin runs below that; the reported figure may understate a lean year. Normalize, below, values the price on that through-cycle figure rather than the latest year.
—
9.0% = the 4.71% 10-year Treasury (Aug 18, 2026) + 4.29 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.71%, as of Aug 18, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings ($143M) on 60M shares outstanding, per the 10-Q cover, as of 2026-07-30; net cash $56M. The base opens on the through-cycle figure (the latest year sits off the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← VMI its page in the Manual VNO →
Industry order: ← UTHR the Pharmaceuticals chapter VRDN →